In its weekly bulletin of December 27, released on Monday, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) said global outbreaks of SARS-CoV-2 are increasingly shifting from Delta to Omicron.
The study describes a new blood test which pinpoints the immune system molecules called antibodies in infected individuals that specifically target a unique piece of the novel coronavirus SARS-CoV-2's spike protein.
"The COVID-19 cases are rising, but hospitalization and deaths are still less," said sources.
While Lupin is working on a Remdesivir powder for inhalation, Glenmark has tied up with a Canadian Biotech firm for nitric oxide nasal spray that reduces Sars-CoV-2 viral load and thus transmission.
During a virtual meeting with health ministers and senior officials of states in view of the recent surge in coronavirus cases in some parts of the world, he said, "The Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for Covid prevention and management."
COVID-19 may be a seasonal infection linked to low temperatures and humidity, much like seasonal influenza, according to new 'robust' evidence found by researchers.
Omicron can evade the immune protection conferred by COVID-19 vaccines and natural infection, according to a peer-reviewed study which also suggests that the new variant of coronavirus is completely resistant to antibody therapies in use today.
Senior virologist Shahid Jameel on Sunday resigned as the chairman of scientific advisory group of Indian SARS-CoV-2 Genomics Consortium, a forum set up by union government in December last year for laboratory and epidemiological surveillance of circulating strains of COVID-19 in India.
'Given that the globally most prevalent clade of SARS-CoV-2 is also predominant in India, any vaccine or drug that gets developed in the world should also prove effective in India'
He also said that it was wrong to suggest that India stopped foreign made vaccines like that made by Moderna and Pfizer from coming to India.
Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
There is no word yet on the progress of rescue operations for the accommodation barge SS-3 and the Sagar Bhushan oil rig.
The research, published in the journal Scientific Reports, provided the first experimental evidence on the capacity of SARS-CoV-2, the virus that causes COVID-19 disease, to infect and be transmitted by mosquitoes.
Amid a gradual rise in daily Covid-19 cases, the Union health ministry said on Thursday that the XBB.1.16 subvariant of Omicron might be the dominant virus strain in the country but there has been no reported increase in the rate of hospitalisation or death so far.
The United States intelligence community has failed to reach any firm conclusion on the exact origin of COVID-19 and is split on whether it leaked from a lab in China or emerged in nature, even though it does not believe the virus was developed as a biological weapon, according to results of a detailed review ordered by President Joe Biden.
The ICMR claimed that no country has yet reported successful isolation and culture of the UK-variant of SARS-CoV-2.
The findings, published in the Journal of Medical Virology, indicate that some of these products might be useful for reducing the viral load, or amount of virus, in the mouth after infection.
'The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of COVID-19,' the apex health research body said on Thursday. The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and Drugs Controller General of India would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the ICMR said.
The research, published in the journal JAMA Pediatrics, is the first large-scale study to compare the health outcomes of coronavirus infection from Omicron and Delta in the age group which is not yet vaccinated.
The rapid molecular test is highly accurate and easy to use, making it a prime candidate for use in settings with limited testing capabilities, according to the researchers.
Most Indians have acquired hybrid immunity which means immunity developed through vaccines and also natural infection protecting them from different COVID-19 variants.
Named after Satyajit Ray's famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.
'FBI Director Christopher Wray confirmed that the Bureau has assessed that the origins of the COVID-19 pandemic likely originated from a lab incident in Wuhan, China,' tweeted the FBI.
The team led by researchers at the University of Maryland in the United States found that people infected with SARS-CoV-2 exhale infectious virus in their breath, and those infected with the Alpha variant put 43 to 100 times more virus into the air than people infected with the original strains of the virus.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
The 'antisera' has been developed by the ICMR in collaboration with a Hyderabad-based bio-pharmaceutical firm. "With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting clinical trials for that," ICMR Director General Dr Balram Bhargava said at press briefing.
The new and highly transmissible Omicron variant of the deadly coronavirus has increased immune escape compared with the Delta variant and appears likely to become the dominant SARS-CoV-2 strain globally in 2022, according to Singapore-based experts.
The committee acknowledged that the COVID-19 pandemic may be approaching an "inflexion point".
Powered by a 996cc engine, the transmission is a CVT unit that transfers power to the front wheels.
A new variant of SARS-CoV-2, the virus which cause COVID-19, has been detected in South Africa and many other countries globally which could be more transmissible and evade protection provided by vaccines, according to study.
'Delta continues to be the dominant lineage for new cases across all parts of India in recent samples and remains the most rapidly rising lineage globally that is responsible for multiple outbreaks, including across Southeast Asia, which shows the fastest growth in new cases globally,' the INSACOG said.
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.
The endemic stage is when a population learns to live with a virus. It is very different from the epidemic stage when the virus overwhelms a population.
The states were requested to take a stock of hospital preparedness such as availability of drugs and medical oxygen, vaccination coverage against COVID-19 and influenza.
The researchers found an increased risk of deep vein thrombosis -- a blood clot in the leg -- up to three months after COVID-19 infection, pulmonary embolism -- a blood clot in the lung -- up to six months, and a bleeding event up to two months.
The vaccine was well tolerated in all dose groups with no vaccine-related adverse events.
Scientists have used virus-like particles to predict how environmental factors affect the survival of the novel coronavirus on surfaces, and found that the COVID-19 virus may remain infectious longer as temperatures drop in winter.
The study found that after 10 hours, the surrogate genetic material had spread to 41 per cent of sites sampled across the hospital ward, from bed rails to door handles to arm rests in a waiting room to children's toys and books in a play area.
The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far, company sources had said.
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.
